Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT01320397
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- RostaQuo S.p.A.
- Registry
-
NCT01320397 -
2010-022073-34
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Ireland, Italy, Poland
- Registry status
- Unknown status
Technical summary
Registry record NCT01320397. Randomized; quadruple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
- Condition
- Essential Hypertension
- Intervention (Drug)
- Rostafuroxin
- Intervention (Drug)
- Rostafuroxin
- Intervention (Drug)
- Rostafuroxin
- Intervention (Drug)
- Losartan
- Lead sponsor
- RostaQuo S.p.A.
Record details
- Record id
cardio:ct-nct01320397- Content hash
edfce3f056eb474f78de92f39ac39917b37093968da5c06831b90ad727001207